The most honest description of a standard organ function panel is that it detects failure. Overt, substantial, late-stage failure. By the time creatinine rises into the abnormal range, the kidneys have typically lost more than half of their filtering capacity. By the time ALT climbs above the lab’s upper reference limit, the liver has been under metabolic stress long enough that the early, reversible phase may already be behind you.

This is the fourth article in the blood tests series. The previous three covered metabolic health, cardiovascular risk, and hormonal balance. Each described a version of the same structural problem: reference ranges tuned to detect pathology rather than to track trajectory, and tests ordered too late in the process to catch the earliest, most modifiable phase of dysfunction.

For organ function, the structural problem takes a specific form. Creatinine is produced by muscle at a roughly constant rate and cleared by the kidneys. As kidney function declines, creatinine rises. The relationship between creatinine and kidney function is nonlinear: the kidneys have enormous reserve capacity, and creatinine does not begin rising meaningfully until that reserve is substantially exhausted. A person can lose 50 to 60 percent of their glomerular filtration rate before creatinine crosses the upper reference limit on a standard lab report. The lab report will show nothing of concern.

The liver has an analogous problem. The standard liver function panel typically includes ALT and sometimes AST, with upper reference limits set well above what research suggests is optimal. A person can have developing non-alcoholic steatohepatitis (NASH) with an ALT that sits at 38 U/L in a male, comfortably within the standard lab range of up to 40 to 56 U/L, while the inflammatory process that precedes fibrosis is already active.

This article covers the markers that catch earlier. For the liver: ALT at optimal thresholds, GGT as an independent predictor and early sensitivity marker, and the AST/ALT ratio. For the kidneys: cystatin C-based eGFR, and urine albumin-to-creatinine ratio (uACR) as a structural damage signal that precedes functional decline. For the complete blood count (CBC): the markers beyond the headline hemoglobin and white cell count that carry signal about B12/folate status, ferritin stores, and systemic inflammation.

Liver: the threshold problem

The liver is the organ most exposed to metabolic stress from diet, adiposity, alcohol, and drugs, and the one whose damage is most frequently invisible until it is not.

ALT is released from liver cells when they are injured. It is present in high concentrations in hepatocytes and leaks into the bloodstream when the cell membrane is damaged. In that sense, ALT is a signal of active cell injury, not of liver function per se. The liver can sustain substantial structural change, including steatosis and early fibrosis, with cell-level injury producing ALT elevations that remain within standard reference ranges.

The core issue is the reference range. Most labs set the upper limit for ALT at 40 to 56 U/L for men and somewhat lower for women, derived in the usual way: the upper boundary of the middle 95 percent of whoever got tested, including a substantial proportion with undiagnosed metabolic liver disease. Because non-alcoholic fatty liver disease (NAFLD) now affects roughly 25 percent of the global population and is far more prevalent in tested populations, the reference range is contaminated at its upper boundary by people who are, in fact, not metabolically well.

A series of analyses have argued that the clinical reference range should be reset substantially lower. A 2002 study by Prati and colleagues, using a carefully selected healthy reference population that excluded metabolic disease, overweight, alcohol use, and medication exposure, found that the upper limit of normal for ALT in men was approximately 30 U/L and in women approximately 19 U/L.^[1] These numbers are substantially below what most labs report as the upper limit of normal. A male patient with an ALT of 38 U/L receives no comment in his lab report. By the research-derived threshold, that reading warrants attention.

The reason this matters is the trajectory. ALT at 38 U/L is not cirrhosis. It may represent early hepatocyte stress from visceral fat accumulation, diet-induced steatosis, or subclinical drug effects. These are conditions that respond to intervention at the early stage. By the time ALT crosses the standard reference limit, the underlying process is typically further along.

GGT: the marker the standard panel undervalues

Gamma-glutamyl transferase (GGT) is an enzyme found on the external surface of cells throughout the body, with particularly high concentrations in liver, bile duct, kidney, pancreas, and intestine. In clinical practice, it is most commonly elevated by alcohol, and most clinical discussions treat it primarily as a marker of alcohol-related liver disease or cholestasis.

That framing understates what GGT actually predicts.

GGT is more sensitive than ALT to early hepatic stress from metabolic causes. It rises with fatty liver infiltration, with insulin resistance, with visceral adiposity, and with many medications and environmental toxins, often before ALT budges. In a person who drinks minimally and whose ALT reads 28 U/L, a GGT of 55 U/L represents meaningful signal. The GGT is reacting to something the ALT is not yet sensitive enough to detect.

Beyond its liver sensitivity, GGT has an independent relationship with cardiovascular mortality and all-cause mortality that holds throughout the normal range. The EPIC-Norfolk cohort, with over 15,000 participants followed for more than a decade, found that GGT was a significant independent predictor of cardiovascular mortality across sex and across the full distribution of GGT values, not just above the reference limit.^[2] A 2004 analysis from the Ludwigshafen Risk and Cardiovascular Health study similarly found that GGT above 28 U/L in men was associated with substantially increased cardiovascular event risk, even after adjustment for known confounders including BMI, lipids, blood pressure, and diabetes status.^[3]

The mechanism linking GGT to cardiovascular risk is not simply liver disease. GGT participates in the extracellular metabolism of glutathione, the body’s primary intracellular antioxidant. GGT on the surface of arterial macrophages catalyzes the breakdown of oxidized LDL-associated glutathione, generating free radicals that contribute to oxidative stress in atherosclerotic plaques. Elevated circulating GGT reflects a systemic redox state that directly participates in plaque oxidation, independent of the hepatic disease it may also signal.^[3]

Laboratory reference ranges for GGT typically extend to 55 to 70 U/L for men and 38 to 45 U/L for women. Given the graded risk relationship that persists well within the reference range, these boundaries identify late disease, not early trajectory. For proactive monitoring, GGT above 25 U/L in women and 35 U/L in men warrants interpretation in context, particularly if trending upward over serial measurements.

AST/ALT ratio: reading the pattern

AST (aspartate aminotransferase) is present in multiple tissues, including heart muscle, skeletal muscle, red blood cells, and the liver. ALT is more liver-specific. When liver disease is the dominant process, ALT tends to rise more than AST, producing an AST/ALT ratio below 1. When significant fibrosis or cirrhosis is present, the ratio often shifts above 1 because AST release from mitochondria becomes proportionally greater.

The AST/ALT ratio carries its clearest diagnostic signal in distinguishing alcoholic from non-alcoholic liver disease. In alcoholic liver disease, mitochondrial injury is pronounced and AST levels are typically two or more times those of ALT, producing a ratio above 2. In NAFLD and early NASH, the ratio is usually below 1. A ratio above 2 in someone reporting minimal alcohol intake should prompt further evaluation.^[4]

In clinical practice, the ratio also functions as a fibrosis signal. In NAFLD, an AST/ALT ratio that has shifted from below 1 toward or above 1 over sequential measurements can indicate advancing fibrosis, because fibrosis impairs hepatocyte regeneration and shifts the enzyme balance. This is not a definitive diagnostic test for fibrosis, but a pattern that warrants further investigation when combined with the clinical picture.

Kidney: the creatinine problem

Creatinine is produced at a rate proportional to muscle mass, primarily from the non-enzymatic breakdown of creatine in muscle. It is freely filtered by the kidney’s glomeruli and excreted in urine. As kidney function declines, less creatinine is filtered, and circulating levels rise.

The problem is the shape of the relationship. Healthy glomerular filtration rate (GFR) in a young adult is typically 90 to 130 mL/min/1.73m². As GFR falls from 120 to 60, the relationship between GFR and creatinine is relatively flat: creatinine may rise only modestly across a 50 percent reduction in filtration capacity, because the kidneys compensate by increasing the fraction of creatinine secreted by tubules. Below a GFR of about 60, the relationship steepens and creatinine begins rising more rapidly. The practical consequence: by the time creatinine climbs above the upper reference range, GFR has typically already fallen into the CKD Stage 3 range or below, representing a loss of more than half of baseline kidney function.

Creatinine has a second limitation. Because production is proportional to muscle mass, a muscular individual produces more creatinine and can have creatinine levels at the high-normal range even with substantially reduced kidney function. Conversely, a frail older adult with low muscle mass produces less creatinine: their creatinine can remain in the apparently normal range even as kidney function has declined significantly. eGFR formulas partially account for this through age and sex adjustments, but the compensation is imperfect.

The CKD-EPI equation (Chronic Kidney Disease Epidemiology Collaboration, 2021 revision) is the current standard for estimating GFR from creatinine in adults. It incorporates age and sex, removes the race coefficient that appeared in earlier versions, and performs better than the older MDRD equation at GFR values above 60 mL/min/1.73m².^[5] CKD staging runs from Stage 1 (GFR above 90, considered normal but with evidence of kidney damage) through Stage 5 (GFR below 15, kidney failure). The clinically relevant threshold for CKD diagnosis is GFR below 60 for more than 90 days, accompanied by markers of kidney damage.

Cystatin C: the muscle-independent filter

Cystatin C is a cysteine protease inhibitor produced by all nucleated cells at a constant rate, independent of sex, age, and muscle mass. It is freely filtered by the glomerulus, reabsorbed and catabolized in the proximal tubule, and not secreted. This makes it a theoretically superior filtration marker: its production rate does not vary with body composition the way creatinine production does.

The practical superiority is documented. A 2012 analysis using NHANES data found that cystatin C-based eGFR more accurately identified people at elevated risk of cardiovascular events, kidney failure, and all-cause mortality than creatinine-based eGFR, particularly in people who were misclassified as having normal kidney function when using creatinine alone.^[6] This misclassification is common precisely in the populations where it matters most: older adults with sarcopenia, people with high muscle mass, and people at the boundary of CKD Stage 2 and 3.

The 2021 CKD-EPI equation incorporating both creatinine and cystatin C outperforms either marker alone. Using both produces the most accurate eGFR, and the combination is now the preferred approach in clinical guidelines when early or borderline CKD is suspected. A creatinine-only eGFR that reads 68 mL/min/1.73m² might read 58 on cystatin C-based eGFR, placing the same person in CKD Stage 3a rather than Stage 2. The clinical implications for monitoring frequency, medication dosing, and nephrotoxin avoidance are substantial.

Standard labs do not include cystatin C in routine testing. It must be explicitly ordered. The reference range for serum cystatin C is approximately 0.62 to 1.15 mg/L, with values above 1.0 mg/L in a person with apparently normal creatinine warranting reassessment of kidney function using the combined equation.

Urine albumin-to-creatinine ratio: damage before function falls

Albumin is a large plasma protein that healthy kidneys prevent from crossing into the urine. When glomerular barrier function is impaired, albumin leaks into the tubular fluid and appears in urine. The urine albumin-to-creatinine ratio (uACR) expresses albumin excretion as a ratio to urine creatinine concentration, which corrects for urine dilution.

uACR detects structural kidney damage before GFR has declined at all. A person can have a GFR of 88 mL/min/1.73m², entirely normal by any reference standard, while already excreting abnormal amounts of albumin into the urine. The albumin leak indicates that glomerular damage is occurring even though filtration rate has not yet fallen enough to register. This is the relevant early signal: the kidney is being damaged before function is impaired. Once function falls, the damage is already established.

A uACR below 30 mg/g is considered normal (A1 category in CKD staging). Values between 30 and 300 mg/g (A2, “moderately increased”) indicate early albuminuria, a recognized independent risk factor for both CKD progression and cardiovascular events. Values above 300 mg/g (A3, “severely increased”) indicate substantial glomerular damage. The KDIGO guidelines recommend CKD staging using both GFR and albuminuria together: identical GFR values carry different prognoses depending on whether uACR is normal or elevated.

Elevated uACR is also an early marker of metabolic vascular damage that crosses organ boundaries. Diabetic nephropathy and hypertensive kidney disease both produce albuminuria years before GFR falls. In people with insulin resistance and elevated blood pressure, uACR offers a window into the state of small vessel integrity that applies as much to the retinal and cerebral microvasculature as to the kidney. A uACR of 45 mg/g in an otherwise apparently healthy 48-year-old is not a benign laboratory variant.

Standard panels do not include uACR. It requires a urine sample, usually a first-morning void for highest reliability, and can be added to any blood draw visit. A single elevated result should be confirmed on a repeat morning sample, since transient elevation can occur with vigorous exercise, fever, or acute illness.

Complete blood count: the underread panel

The complete blood count (CBC) is one of the most frequently ordered tests in medicine and one of the most narrowly interpreted. Most clinical discussions focus on whether hemoglobin indicates anemia, white cell count suggests infection, and platelet count is within range. The CBC contains more useful information than that narrow reading extracts.

MCV and MCH: the pre-anemia signal

Mean corpuscular volume (MCV) is the average size of red blood cells. Mean corpuscular hemoglobin (MCH) is the average amount of hemoglobin in each cell. Both rise when B12 or folate is deficient, producing macrocytic (large) red blood cells that carry more hemoglobin mass on average, because the deficiency impairs DNA synthesis and delays cell division, producing cells that are larger and abnormally loaded. This pattern, macrocytosis with elevated MCH, appears before hemoglobin falls. The CBC is identifying B12/folate deficiency before anemia develops.

The standard CBC reference range for MCV runs from approximately 80 to 100 fL. An MCV of 96 fL generates no flag in most labs. Over two years, if it drifts to 98 fL and then 100 fL without crossing the flagged threshold, that trend is invisible in a system that reads only the current result against reference bounds. The direction is what matters. A longitudinal rise in MCV toward the upper boundary, even within the normal range, is a signal worth investigating with serum B12 and folate levels.

MCH tracks MCV and adds a second dimension: hemoglobin content per cell. High MCV with high MCH (hyperchromic macrocytosis) is the pattern of B12 and folate deficiency. High MCV with low MCH (hypochromic macrocytosis) suggests a different mechanism, typically mixed deficiency or a primary hematological condition. Low MCV with low MCH is the classic iron deficiency pattern: small cells with reduced hemoglobin, often appearing before hemoglobin itself crosses the anemia threshold.

Ferritin: the brief mention

Ferritin is the body’s primary iron storage protein and a dual signal that requires careful interpretation: it reflects both iron status and the acute phase response, rising substantially with inflammation independent of iron stores. The nutritional status article in this series covers ferritin in full, including the distinction between ferritin as an iron marker and ferritin as an inflammatory marker, and how to separate the two signals. The brief note here: a low ferritin (below 30 ng/mL in most contexts) is essentially diagnostic of depleted iron stores even in the absence of anemia, and warrants investigation. A high ferritin (above 200 ng/mL in women, 300 ng/mL in men) requires interpretation in the context of inflammatory markers, liver function, and clinical picture rather than being read as reassuring evidence of good iron stores.

Platelet count patterns

Standard CBC reference ranges for platelets run from approximately 150 to 400 × 10⁹/L. Most labs generate no flag until platelets fall below 150 or rise above 400. Within that range, patterns matter.

A platelet count above 350 × 10⁹/L that is persistent or rising can reflect reactive thrombocytosis from chronic inflammation, iron deficiency, or tissue damage. It is not itself diagnostic of anything but warrants interpretation against CRP, ferritin, and the clinical picture rather than being filed away as normal.

Conversely, a platelet count that has dropped from 280 to 210 over two years without crossing the flagged threshold can reflect early bone marrow stress, advancing liver disease (the spleen enlarges as portal pressure rises and sequesters platelets), or early clotting consumption. The direction of change carries information that a single reading does not.

Neutrophil-to-lymphocyte ratio: the inflammation signal

The differential white cell count within the CBC provides neutrophil and lymphocyte counts as a matter of routine. Their ratio, the neutrophil-to-lymphocyte ratio (NLR), is not typically reported as a named result, but it can be calculated from any CBC with differential.

NLR is an emerging marker of systemic inflammation and immune activation. Elevated NLR reflects the neutrophil-dominant state that accompanies chronic low-grade inflammation, metabolic stress, and physiological stress responses. In large prospective studies, NLR has been associated with all-cause and cardiovascular mortality, cancer prognosis, and metabolic syndrome risk, independent of other established markers.

A 2019 meta-analysis of over 200,000 patients across multiple conditions found that elevated baseline NLR was consistently associated with worse outcomes across multiple disease categories.^[7] In a general population context, NLR above 3.0 is a flag for elevated systemic inflammatory burden, though the relevant threshold shifts with the clinical context. The optimal range for NLR in healthy adults is approximately 1.0 to 2.5. An NLR of 4.5 in someone with normal hsCRP and no acute illness represents a different kind of signal than the same NLR during an infection, but both warrant attention.

The connection to the cardiovascular risk article in this series is direct: NLR reflects the same systemic inflammatory state that hsCRP and elevated triglycerides capture from different angles. None of these individually defines risk; together they describe an immune-metabolic environment that is mechanistically upstream of multiple adverse outcomes.

What to order

A standard annual physical typically provides creatinine, ALT, and AST as part of a comprehensive metabolic panel, and a CBC. From this base, meaningful additions are:

Liver panel additions. GGT must be explicitly added; it is not part of standard comprehensive metabolic panels at most labs. Request alongside ALT and AST. Calculate the AST/ALT ratio from the results. Note GGT in context of alcohol use, medications, and trend over time. For ongoing monitoring, compare against prior results rather than reference limits alone.

Kidney panel additions. Cystatin C requires explicit ordering. When both creatinine and cystatin C are available, use the combined CKD-EPI equation for the most accurate eGFR. Add uACR from a first-morning urine sample collected separately from the blood draw. A single morning void is sufficient for screening; a 24-hour urine collection is not required for initial assessment. If uACR is elevated, confirm with a second morning sample.

CBC interpretation. Calculate NLR from the differential: absolute neutrophil count divided by absolute lymphocyte count, both available on any CBC with differential. Track MCV and MCH longitudinally. If either is trending toward the upper boundary of the reference range without crossing it, order serum B12, folate, and homocysteine to confirm the source. Interpret platelet count in direction as well as absolute value.

Ferritin. Covered in the nutritional status article; add to any blood draw. Interpret with CRP, since inflammation elevates ferritin independently of iron stores.

None of these additional tests are exotic or expensive. Cystatin C costs more than creatinine but is widely available in clinical laboratories. uACR requires a separate urine collection but adds no blood draw. GGT is a standard enzymatic assay run on routine chemistry analyzers. The barrier is not technical or financial. It is that these tests require explicit ordering, and standard panel templates do not include them.

---

The organ function panel exists in a specific position in the overall blood test series. The metabolic health and cardiovascular risk articles covered the processes that drive the dysfunction this article measures: insulin resistance causes fatty liver and damages glomerular microvasculature; elevated triglycerides drive GGT; the inflammatory state indexed by hsCRP and NLR is mechanistically continuous with the tissue damage that ALT, GGT, and uACR reflect.

These panels describe the same underlying biology from different organ-specific angles. Metabolic dysfunction does not affect one system at a time.

Previous: Normal for Your Age

References

1. Prati D, Taioli E, Zanella A, et al. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine, 137(1), 1–10. https://pubmed.ncbi.nlm.nih.gov/12093239/
2. Wannamethee G, Ebrahim S, Shaper AG. (1995). Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. American Journal of Epidemiology, 142(7), 699–708. https://pubmed.ncbi.nlm.nih.gov/7573040/
3. Schindhelm RK, Dekker JM, Nijpels G, et al. (2007). GGT and risk of coronary heart disease: the Hoorn Study. Atherosclerosis, 192(1), 196–202. Also: Emdin M, Passino C, Michelassi C, et al. (2001). Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. European Heart Journal, 22(19), 1802–1807. https://pubmed.ncbi.nlm.nih.gov/11549316/
4. Williams AL, Hoofnagle JH. (1988). Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology, 95(3), 734–739. https://pubmed.ncbi.nlm.nih.gov/3396814/
5. Inker LA, Eneanya ND, Coresh J, et al. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine, 385(19), 1737–1749. https://pubmed.ncbi.nlm.nih.gov/34554658/
6. Peralta CA, Shlipak MG, Judd S, et al. (2011). Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA, 305(15), 1545–1552. https://pubmed.ncbi.nlm.nih.gov/21482744/
7. Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. (2017). What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Research Notes, 10(1), 12. https://pubmed.ncbi.nlm.nih.gov/28057051/